The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If the site developer(s) were not using the https://medusa19.com web address to develop and make constant changes on, we would be none the wiser would we?
1 They will publish more incorrect info this way.
2 They will publish accurate info that is not in the public domain.
These two concerns will make Al's ulcer play up I'm sure, and I would not be surprised if the website is inaccessible by tonight.
Spike,
Agree totally, we just need to wait for a RNS and if this info is correct on the website, it will be announced Mon 0700hrs..
gla
I think we established yesterday that the lay out on the website presented differently depending on the device you were using. That gave rise to differing interpretations of whether there was just one test being promoted or two. Medusa also edited their wording on their Life Sciences product mid-discussion. It seems that they were trying to show that this is an antibody test but, in my opinion, the wording is still very poor. It doesn’t trouble me because I suspect this is just a draft, the final version should be bang on, hopefully. It does seem that someone accidentally left the curtains open and may be in for a rollicking!!!
Despite the confusion caused, I do feel that we have reason for increased confidence having seen what is going on in the background. Next week should be very interesting
Gmcc No expert but that sounds like a huge stride forwards to me!
'Affimers have higher specifity than old school monoclonal antibodies'
Another tick in the box.
Maltby How do you know last buys were on a false premise?
There only 4 buys and all in the range of 10-15k looks solid to me.
out of my depth but did find this article
https://www.sciencedirect.com/science/article/pii/S1046592820301182
"Affimers as an alternative to antibodies for protein biomarker enrichment"
"Conclusions
For both proteins tested, affimers show higher specificity in purifying their target proteins from human plasma compared to monoclonal antibodies. These results indicate that affimers are promising antibody-replacement tools for protein biomarker assay development.
Thank you, Maltby, for this very clear and correct interpretation. It is always better to work from original sources and the best we have is what appeared, and was later altered, on the Medusa site. The Medusa Life Science test is an antibody test, it will not be in competition with Avacta's antigen test and, if we trust Alistair Smith and his team as most of us clearly do, I am more than happy to back the distribution deals he strikes for a therapy which means far more to him than it can ever to do us. The company is his life whereas to us it is an investment opportunity which we can take or leave as we like. I would never back a company whose leadership I was not happy to trust but, from the outside looking in, everything I have seen and read sits well with me. That is why the timing of THE big RNS is not of any concern - I know nothing about scientific research but I do understand timescales when it comes to the importance of accuracy and reliability of data and I am happy to wait for as long as it takes the team to validate and publish the data.
Thanks for providing clarity all a bit confusing for the customer ?
Ideally one test would be ideal that caters for all prognosis , identify at any time in an individual
----whether they have symptoms or not, to be identified before antibodies have been generated by the body -----and or if antibodies exist early indication of the immune response to the SARS-CoV-2 virus that is highly accurate in indicating the virus in asymptomatic patients.
Can Avacta affimers identify antibodies - maybe their test could be adapted to cater for this requirement in any later development ?
Anyway might be confusing for the individual on which test to purchase or indeed persuade them to purchase two different tests ?
Avacta :
"The test being created by Avacta and its partners is intended to enable an individual with the COVID19 infection, whether they have symptoms or not, to be identified before antibodies have been generated by the body. Given this test will be saliva based, it could be used in airports, offices, factories and in the home environment, providing a result within minutes and with no requirement for medical supervision. It is potentially ground-breaking and a major step forward in the fight against COVID-19."
Medusa 19 Life Sciences
Medusa 19 are working with their partner, Medusa 19 Life Sciences, to exclusively bring to market the best in class saliva lateral flow test for early indication of the immune response to the SARS-CoV-2 virus that is highly accurate in indicating the virus in asymptomatic patients.
The Rapid Saliva Protein Test (RSPT) is a simple, non-invasive, on the spot test indicating infection from SARS-CoV-2, the virus underlying COVID-19."
Anyway both products "coming soon" which is good news !
Just trying to get a bit of clarity from the excitement following the updated Medusa web site:
- the test published on this site is clearly an antibody test as confirmed by their late inclusion of the word immunity and to that extent the late flurry of buys in the last 15 minutes was based on a false premise.
- Medusa’s web site makes clear they will not market antigen tests that compete with AVCT and there will be no need for Al to RNS on Monday any clarification as initially suggested.
- Plenty of bad press on Medusa that I do not subscribe to. They didn’t jump the gun as it is not AVCT‘s test and they have some very experienced professionals in their team with a lot more retail experience than the people who are criticising them.
- There is clearly a lot going on behind the scenes re infrastructure, manufacturing partners etc indicating the extent of the global market that is potentially available to AVCT.
- In the meantime the clinical validation process continues, the excitement builds and we are a day nearer to the news w are all hoping to wake up to.